Article Text

Download PDFPDF

CASE REPORT
Sinonasal relapses of a primary isolated extranodal NK/T-cell lymphoma of the testis
  1. Bassel Hallak1,
  2. Anne Cairoli2,
  3. Salim Bouayed1 and
  4. Grégoire Berthod3
  1. 1 Department of Otorhinolaryngology, Hospital of Sion, Sion, Switzerland
  2. 2 Hematology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  3. 3 Oncology, Hospital of Sion, Sion, Switzerland
  1. Correspondence to Dr Bassel Hallak, bassel2004{at}hotmail.com

Abstract

WHO first recognised extranodal NK/T-cell lymphoma (ENKTCL) in 2001, thanks to technical advances in anatomopathology and immunohistochemistry. It is divided into nasal and extranasal subgroups depending on the primary site. Primary isolated NK/T-cell lymphoma of the testis is rare. Typical recurrence sites of primary testicular NK/T-cell lymphoma are the gastrointestinal tract, lymph nodes, skin, spleen and central nervous system. Nasal relapses of a primary NK/T-cell lymphoma of the testis are very rare and according to our knowledge, no other case has been reported yet in the literature. The authors report the case of a 35-year-old Caucasian man relapsing twice in the nasal cavity 1 year after initial diagnosis and treatment of a primary isolated, stage IE, ENKTCL of the testis. We report the clinical and radiological presentation of the nasal relapses and the different modalities of treatment that were applied. Sinonasal relapses of an isolated primary NK/T-cell lymphoma of the testis are very rare. ENKTCL is a very aggressive entity, even at an early stage, therefore, requiring a multimodal treatment approach including chemotherapy and radiotherapy. New strategies to treat this disease are needed.

  • cancer - see oncology
  • ear, nose and throat
  • radiotherapy

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors BH, corresponding author, reporting. AC, coauthor, acquisition of date. SB, coauthor, design. GB, coauthor, reporting.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.